BridgeBio Pharma, Inc.
BBIO
Rang în acțiuni
#1619
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying,... BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
Preț acțiune
$67.62
Capitalizare de piață
$13.22B
Schimbare (1 zi)
-0.48%
Schimbare (1 an)
20.19%
Țară
US
Tranzacționează BridgeBio Pharma, Inc. (BBIO)
Categorie
Healthcare
Venituri pentru BridgeBio Pharma, Inc. (BBIO)
Venituri în Jun 2026 TTM: $713.07M
Conform celor mai recente rapoarte financiare ale BridgeBio Pharma, Inc., venitul actual al companiei (TTM) este $713.07M. În anul 2023, compania a avut un venit de $9.30M o scădere comparativ cu venitul din anul 2022, care a fost de $77.65M. Venitul reprezintă suma totală generată de o companie din vânzarea de bunuri sau servicii. Spre deosebire de profit, cheltuielile nu sunt scăzute.
Istoricul veniturilor pentru BridgeBio Pharma, Inc. din 2017 până în 2026
Venituri la sfârșitul fiecărui an
| An | Venituri | Schimbă |
|---|---|---|
| 2026 (TTM) | $713.07M | 221.35% |
| 2024 | $221.90M | 2,285.27% |
| 2023 | $9.30M | -88.02% |
| 2022 | $77.65M | 11.38% |
| 2021 | $69.72M | 745.14% |
| 2020 | $8.25M | -79.66% |
| 2019 | $40.56M | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
Venituri pentru companii similare sau concurente
| Companie | Venituri | Diferență de venituri | Țara |
|---|---|---|---|
| $12.62B | 1,670.41% |
US
|
|
| $2.23B | 212.45% |
US
|
|
| $15.74B | 2,107.96% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 744.42% |
NL
|
